Communiqués IRLAB Therapeutics AB

Actions

IRLAB A

SE0012675361

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
16 ^SEK	+0,95 %		+7,38 %	+113,33 %

10/07	Transcript : IRLAB Therapeutics AB, H1 2024 Earnings Call, Jul 10, 2024
10/07	IRLAB Therapeutics AB (publ) publie ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

IRLAB publishes interim report for the period January-June 2024	10/07	AQ
IRLAB, Invitation to the interim report for Q2 2024 presentation and webcast	09/07	AQ
IRLAB: Invitation to the interim report for Q2 2024 presentation and webcast	08/07	AQ
IRLAB's Phase IIb study of pirepemat can proceed as planned after positive opinion from external safety committee	02/07	AQ
IRLAB participates in Stora Aktiedagarna	11/06	AQ
IRLAB appoints Kristina Torfgard as new CEO	28/05	AQ
IRLAB presents at Redeye Growth Day 30 May	28/05	AQ
IRLAB appoints Kristina Torfgård as new CEO	27/05	AQ
IRLAB strengthens its liquidity by drawing SEK 25 million on a previously secured loan facility	23/05	AQ
Report from the Annual General Meeting 2024 of IRLAB Therapeutics AB	22/05	AQ
IRLAB has administered the first dose in a Phase I clinical trial with the drug candidate IRL757	22/05	AQ
IRLAB broadcasts the annual general meeting live	22/05	AQ
IRLAB presents at ABGSC Investor Days	21/05	AQ
IRLAB publishes interim report for the period January-March 2024	08/05	AQ
IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy	07/05	AQ
IRLAB has received approval from the Swedish Medical Products Agency to conduct a Phase I study of the drug candidate IRL757	06/05	AQ
IRLAB: Invitation to the interim report for Q1 2024 presentation and webcast	06/05	AQ
IRLAB publishes Annual Report for 2023	29/04	AQ
IRLAB to present at Redeye Investor Forum	16/04	AQ
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	25/03	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués IRLAB Therapeutics AB

Actions

IRLAB A

SE0012675361

Communiqués

Filtres